Research programme: Psychiatric disorder therapies - Gate Neurosciences
Latest Information Update: 02 Aug 2024
Price :
$50 *
At a glance
- Originator Gate Neurosciences
- Class Behavioural disorder therapies; Neuropsychotherapeutics
- Mechanism of Action Insulin-like growth factor binding protein 2 modulators; Metabotropic glutamate receptor 2 agonists; Metabotropic glutamate receptor 2 modulators; Metabotropic glutamate receptor 3 modulators; NMDA receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders; Psychiatric disorders
Most Recent Events
- 02 Aug 2024 Discontinued - Preclinical for Neurological disorders in USA (unspecified route) (Gate Neurosciences pipeline, February 2024)
- 24 Jul 2024 Discontinued - Preclinical for Psychiatric disorders in USA (unspecified route) (Gate Neuroscinces pipeline, July 2024)
- 24 Jul 2024 Preclinical trials in Neurological disorders in USA (unspecified route) before February 2024 (Gate Neurosciences pipeline, February 2024)